Translational advances in pancreatic ductal adenocarcinoma therapy

Area of Science:

• Oncology
• Cancer Research
• Translational Medicine

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy.
• Late-stage diagnosis limits treatment options, primarily to systemic chemotherapy with suboptimal outcomes.

Purpose of the Study:

• To review recent advancements in targeted therapy and immunotherapy for PDAC.
• To evaluate preclinical and clinical evidence for novel therapeutic strategies.
• To highlight the potential of combinatorial regimens in improving patient survival.

Main Methods:

• Literature review of recent preclinical and clinical studies.
• Analysis of molecular alterations driving PDAC subtypes.
• Assessment of targeted therapy and immunotherapy efficacy.

Main Results:

• Emerging targeted therapies show promise for specific PDAC molecular subtypes.
• Immunotherapy approaches are being investigated for their potential in PDAC treatment.
• Combinatorial strategies may overcome treatment resistance and enhance clinical responses.

Conclusions:

• Targeted therapy and immunotherapy represent promising avenues for PDAC treatment.
• Further research and clinical trials are crucial to validate these approaches.
• Personalized medicine strategies hold potential to improve outcomes for PDAC patients.